11月28日 - ** 制药商旺达制药VNDA.O股价盘前下跌1.1%，报5.14美元
** 该公司称，美国 FDA 已要求延期，以完成对其实验性晕车药曲替匹坦长期研究部分暂停的审查。
** VNDA 称，美国 FDA 将在 2025 年 12 月 5 日前完成对该限制的快速复审，而不是原定的 11 月 26 日最后期限。
** FDA已开始就替替匹坦的 "新药申请 "进行标签讨论；PDUFA行动日期仍为12月30日 - VNDA
** 截至上次收盘，股价年累计上涨约 11
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.